Key Points - Adjusted earnings per share (Non-GAAP) reached $5.46 for Q2 2025, up 37% year over year and surpassing analyst expectations by 16 %. Revenue (GAAP) climbed 8% year over year to $7.0 ...

But, if its pipeline of new products comes into play, including work on new treatments in oncology, then Moderna stock -- down 74% in the year ending July 21 -- might have some great long-term ...